These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27412701)

  • 1. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
    Shomali ME; Ørsted DD; Cannon AJ
    Diabet Med; 2017 Feb; 34(2):197-203. PubMed ID: 27412701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.
    Davidson JA; Ørsted DD; Campos C
    Diabetes Obes Metab; 2016 Jul; 18(7):725-8. PubMed ID: 26936426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
    Bode BW; Brett J; Falahati A; Pratley RE
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
    Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
    Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.
    Seufert J; Bailey T; Barkholt Christensen S; Nauck MA
    Diabetes Obes Metab; 2016 Jul; 18(7):721-4. PubMed ID: 26679282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
    Kaku K; Rasmussen MF; Clauson P; Seino Y
    Diabetes Obes Metab; 2010 Apr; 12(4):341-7. PubMed ID: 20380655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
    Miyagawa J; Odawara M; Takamura T; Iwamoto N; Takita Y; Imaoka T
    Diabetes Obes Metab; 2015 Oct; 17(10):974-83. PubMed ID: 26179187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
    Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
    Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
    Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
    Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
    Brady EM; Davies MJ; Gray LJ; Saeed MA; Smith D; Hanif W; Khunti K
    Diabetes Obes Metab; 2014 Jun; 16(6):527-36. PubMed ID: 24373063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.